Skip to Main Content

Paper Details

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Multiple Sclerosis Journal
29
2019
Ozanimod, RADIANCE, atrioventricular block, gadolinium, multiple sclerosis, opportunistic infection, ozanimod, ozanimod hydrochloride, participants, sphingosine 1-phosphate, sphingosine 1-phosphate receptors 1 and 5
Author NameAffiliation
Giancarlo ComiSan Raffaele Scientific Institute, Vita-Salute San Raffaele University
Krzysztof SelmajCenter for Neurology
Bruce A C CreeUCSF Weill Institute for Neurosciences and Department of Neurology, University of California san francisco
Xavier MontalbanDivision of Neurology and St. Michael's Hospital, University of Toronto, Vall d'Hebron University Hospital and Universitat Autonoma de Barcelona
Hans-Peter HartungHeinrich Heine University
  • 1 - 5

Datasets

Release 1.2